Abstract:Lymphatic filariasis (LF) causes chronic morbidity, which usually manifests as lymphedema or hydrocele. Mass drug administration (MDA) began in Kassena Nankana East Municipal (KNEM) and Nabdam, two hotspot districts in the Upper East Region in Ghana, in 2000 and 2005, respectively. This cross-sectional study evaluated the impact of 15 years of MDA on the control of LF as determined by circulating filarial antigen (CFA) and microfilariae assessment in the KNEM and the Nabdam districts. A total of 7,453 participants from eight sub-districts in the two hotspot districts (KNEM: N = 4604; Nabdam: N = 2849) were recruited into the study. The overall CFA prevalence as determined by the FTS was 19.6% and 12.8% in the KNEM and Nabdam districts, respectively. Manyoro, a sub-district on the border with Burkina Faso, recorded the highest CFA prevalence of 26% in the KNEM. Assessment of microfilariae and Og4C3 antigen was done from 1009 (KNEM: N = 799 (79.2%); Nabdam: N = 210 (20.8%)) randomly selected FTS-positive (N = 885) and FTS-negative (N = 124) individuals. The Og4C3 antigen was found in 22.6%/23.0% of the selected individuals (KNEM/Nabdam), whereas the night blood revealed microfilariae in only 0.7%/0.5%. Using the WHO endorsed FTS, CFA prevalence exceeded the long-standing <2% threshold—which may need revision and validation. Surprisingly, the Og4C3 ELISA showed positive results in only about one-fifth of the FTS positive samples. However, even this result would not have met the <2% CFA criteria for LF elimination. In contrast, projections from the microfilariae results revealed a halt in LF transmission. The global elimination target was due in 2020 but has been extended to 2030 since this could not be met. Focused MDA intervention intensification on seasonal migrants and non-compliers, and implementation of alternative treatment strategies may suffice for the elimination of the disease. Lymphatic filariasis (LF) is a major neglected tropical disease (NTD) affecting over 120 million individuals worldwide and identified as one of WHO's 20 NTDs targeted for elimination. It has strong links with poverty and is associated with significant clinical morbidity, which impose considerable socio-psychological and economic burdens on the affected individuals. One of the main goals of the Global Programme to Eliminate Lymphatic Filariasis (GPELF) is the use of mass drug administration (MDA) to interrupt LF transmission. The initial 2020 elimination target year set by the GPELF could not be met, with 2030 now the new proposed year targeted for global elimination. The study evaluated the impact of 15 years of MDA on the control of LF in two hotspot districts in Ghana. The results from this study are indicative of a halt in LF transmission in the districts, with microfilaria detected in <1% of those sampled. However, the prevalence is still above the recommended level. MDA should be intensified especially at the border towns or alternative treatment strategies should be employed to finally eliminate the disease as some people who are still with the active infection can serve as a reservoir for recrudescence and transmission in already "LF-free" areas.

Triple-drug therapy with ivermectin, diethylcarbamazine and albendazole for the acceleration of lymphatic filariasis elimination in Kenya: Programmatic implementation and results of the first impact surveillance

Triple-drug therapy with ivermectin, diethylcarbamazine and albendazole for the acceleration of lymphatic filariasis elimination in Kenya: Programmatic implementation and results of the first impact assessment

Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach

Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial

Safety and Tolerability of Mass Diethylcarbamazine and Albendazole Administration for the Elimination of Lymphatic Filariasis in Kenya: An Active Surveillance Study

Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: Perceptions and experiences of community drug distributors of coastal Kenya

Predictive Value of Microfilariae-Based Stop-MDA Thresholds After Triple Drug Therapy With IDA Against Lymphatic Filariasis in Treatment-Naive Indian Settings

Occurrence of Lymphatic Filariasis infection after 15 years of mass drug administration in two hotspot districts in the Upper East Region of Ghana

Lymphatic filariasis antigen and microfilaria epidemiology in Samoa in 2019, six months post triple-drug mass drug administration

Ongoing transmission of lymphatic filariasis in Samoa 4.5 years after one round of triple-drug mass drug administration

The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya

Efficacy of ivermectin and albendazole combination in suppressing transmission of lymphatic filariasis following mass administration in Tanzania: a prospective cohort study

Low Microfilaremia Levels in Three Districts in Coastal Ghana with at Least 16 Years of Mass Drug Administration and Persistent Transmission of Lymphatic Filariasis

Factors influencing implementation of mass drug administration for lymphatic filariasis elimination: a mixed-method study in Odisha, India

Evaluation of Mass Drug Administration Coverage for Lymphatic Filariasis in the Lukonga Health Zone in 2022

The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya

Cost-effectiveness of vector control for supplementing mass drug administration for eliminating lymphatic filariasis in India

COMMUNITY MEMBERS' PERCEPTIONS OF MASS DRUG ADMINISTRATION FOR CONTROL OF LYMPHATIC FILARIASIS IN RURAL AND URBAN TANZANIA

Strengthening of mass drug administration implementation is required to eliminate lymphatic filariasis from India: an evaluation study

National mass drug administration costs for lymphatic filariasis elimination

How endemic countries can accelerate lymphatic filariasis elimination? An analytical review to identify strategic and programmatic interventions